AmCad BioMed Corporation reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was TWD 27.24 million compared to TWD 14.46 million a year ago. Net income was TWD 0.029 million compared to net loss of TWD 9.86 million a year ago. For the nine months, sales was TWD 58.94 million compared to TWD 43.93 million a year ago. Net loss was TWD 19.32 million compared to TWD 31.15 million a year ago. Basic loss per share from continuing operations was TWD 0.36 compared to TWD 0.59 a year ago.